BofA lowered the firm’s price target on Ascendis Pharma to $92 from $132 and keeps a Buy rating on the shares. The firm cut its price target after the FDA reported deficiencies during its TransCon PTH NDA review, which the firm assumes base case to lead to a CRL based on a tight timeline.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASND:
- Ascendis Pharma Craters after Disappointing Drug News
- Ascendis Pharma downgraded at Credit Suisse after FDA find deficiencies in NDA
- Ascendis Pharma downgraded to Neutral from Outperform at Credit Suisse
- Ascendis Pharma falls 38% after disclosing FDA notice of deficiencies in NDA
- Ascendis’ Phase 1/2 initial trial results of TransCon accepted for ASCO 2023